LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

LLY

1,076.96

+0.06%↑

JNJ

207.49

-0.14%↓

ABBV

230.16

+0.01%↑

UNH

331.59

+1.17%↑

AZN

92.89

+0.42%↑

Home・Aandelen Lijst・Ventyx Biosciences Inc

Ventyx Biosciences Inc

Gesloten

9.19 0.55

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.13

Max

9.31

Belangrijke statistieken
By Trading Economics
Inkomsten	4.2M -23M
Winstmarge	-2,027.003
Werknemers	83
EBITDA	6.6M -23M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+49.35% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	80M 666M
Vorige openingsprijs	8.64
Vorige sluitingsprijs	9.19

Ventyx Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 dec 2025, 21:41 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20 Billion, CNBC Reports

26 dec 2025, 20:22 UTC

Marktinformatie

Oil Loses Ground On Russia-Ukraine Peace Efforts -- Market Talk

26 dec 2025, 20:13 UTC

Marktinformatie

U.S. Natural Gas Gains on Colder Weather Outlook -- Market Talk

26 dec 2025, 19:24 UTC

Acquisities, Fusies, Overnames

Nvidia's Groq Deal Is an Instagram Moment -- With 1 Big Risk -- Barrons.com

26 dec 2025, 17:45 UTC

Marktinformatie

U.S. Diesel Down on Lower Crude Prices, Freight-Sector Lull -- Market Talk

26 dec 2025, 15:52 UTC

Marktinformatie

Oil Futures Turn Lower After Steady Start -- Market Talk

26 dec 2025, 14:58 UTC

Marktinformatie

Silver, Gold Reach New Highs Amid Geopolitical Tension -- Market Talk

26 dec 2025, 14:41 UTC

Marktinformatie

U.S. Natural Gas Futures Look to End Week Higher -- Market Talk

26 dec 2025, 14:28 UTC

Marktinformatie

Dollar Indexes Flat as Yen Rally Wanes -- Market Talk

26 dec 2025, 13:47 UTC

Marktinformatie

Oil Futures Steady in Thin Holiday Trade -- Market Talk

26 dec 2025, 07:22 UTC

Marktinformatie

Comex Gold Futures' Strong Bullish Momentum in Play, Chart Shows -- Market Talk

26 dec 2025, 05:03 UTC

Marktinformatie

Malaysian Ringgit Likely to Face Pressure From Dollar Strength in 1Q -- Market Talk

26 dec 2025, 03:38 UTC

Marktinformatie

Global Equities Roundup: Market Talk

26 dec 2025, 03:38 UTC

Marktinformatie

Korean Won Strengthens, Supported by Verbal Interventions -- Market Talk

26 dec 2025, 02:44 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

26 dec 2025, 02:44 UTC

Marktinformatie

Singapore Dollar Weakens Slightly on Likely Position Adjustments -- Market Talk

26 dec 2025, 01:39 UTC

Marktinformatie

China's Central Bank Signals Possibility of Easing Policy in Coming Months -- Market Talk

26 dec 2025, 01:14 UTC

Marktinformatie

Oil Edges Higher Amid Geopolitical Tensions -- Market Talk

26 dec 2025, 00:34 UTC

Marktinformatie

Yen Mostly Weakens Amid Risk-on Sentiment -- Market Talk

26 dec 2025, 00:15 UTC

Marktinformatie

Nikkei Gains 0.6%, Led by Tech, Videogame Stocks -- Market Talk

25 dec 2025, 23:42 UTC

Marktinformatie

Nikkei May Trade in Range; Yen in Focus -- Market Talk

25 dec 2025, 23:40 UTC

Marktinformatie

Gold Edges Higher Amid Geopolitical Risks -- Market Talk

25 dec 2025, 00:20 UTC

Acquisities, Fusies, Overnames

Nike Climb Boosts Dow, S&P 500 -- 2nd Update

24 dec 2025, 22:22 UTC

Acquisities, Fusies, Overnames

Nvidia, Groq Strike AI Tech Licensing Deal -- Barrons.com

24 dec 2025, 21:26 UTC

Acquisities, Fusies, Overnames

Nvidia to Buy Chip-Designer Groq for $20B, CNBC Reports

24 dec 2025, 19:35 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

24 dec 2025, 19:35 UTC

Marktinformatie

Treasury Yields Decline Ahead of Christmas -- Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Global Equities Roundup: Market Talk

24 dec 2025, 19:09 UTC

Marktinformatie

Acquisities, Fusies, Overnames

ServiceNow's Armis Acquisition Shouldn't Fuel Fears That Seat-Based Model Threatened -- Market Talk

24 dec 2025, 19:06 UTC

Marktinformatie

Oil Futures Little Changed in Light Pre-Holiday Trade -- Market Talk

Peer Vergelijking

Prijswijziging

Ventyx Biosciences Inc Prognose

Koersdoel

By TipRanks

49.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.71 USD 49.35%

Hoogste 21 USD

Laagste 2 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ventyx Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Ventyx Biosciences Inc - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.